StockNews.com Initiates Coverage on NeuroMetrix (NASDAQ:NURO)

by · The Markets Daily

Equities research analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO – Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Trading Down 2.4 %

Shares of NURO stock opened at $4.00 on Wednesday. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $5.96. The business’s fifty day simple moving average is $3.64 and its 200-day simple moving average is $3.84. The company has a market cap of $8.04 million, a PE ratio of -0.63 and a beta of 2.28.

NeuroMetrix (NASDAQ:NURO – Get Free Report) last announced its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) earnings per share for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. The business had revenue of $0.77 million for the quarter.

NeuroMetrix Company Profile

(Get Free Report)

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.

Further Reading